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Cell stress proteins (CSPs) are a large and heterogenous family of proteins, sharing two main characteristics: their levels and/or
location are modified under stress and most of them can exert a chaperon function inside the cells. Nonetheless, they are also
involved in the modulation of several mechanisms, both at the intracellular and the extracellular compartments. There are more
than 100 proteins belonging to the CSPs family, among them the thioredoxin (TRX) system, which is the focus of the present
paper. TRX system is composed of several proteins such as TRX and peroxiredoxin (PRDX), two thiol-containing enzymes that
are key players in redox homeostasis due to their ability to scavenge potential harmful reactive oxygen species. In addition to their
main role as antioxidants, recent data highlights their function in several processes such as cell signalling, immune inflammatory
responses, or apoptosis, all of them key mechanisms involved in atherothrombosis. Moreover, since TRX and PRDX are present in
the pathological vascular wall and can be secreted under prooxidative conditions to the circulation, several studies have addressed
their role as diagnostic, prognostic, and therapeutic biomarkers of cardiovascular diseases (CVDs).
1. Introduction
The vast majority of the proteins require further assistance
for acquiring proper maturation and stability; this process
described in the late 80s is facilitated through the activity
of a family of proteins called “molecular chaperones” or cell
stress proteins (CSPs) [1]. This large and diverse group of
proteins composed by more than 20 families of proteins and
more than 100 proteins includes the heat shock proteins
(HSPs) and the thioredoxin (TRX) system. The role of
HSPs in cardiovascular diseases (CVDs) has been thoroughly
reviewed [2]. In the present paper, we will focus on the
role of the TRX system, specifically TRX and peroxiredoxins
(PRDXs), in atherothrombosis. For this purpose, we have
followed the PRISMA chart displayed in Supplementary
Figure 1 (see Suppplementary Figure 1 in supplementary
material available online at doi:10.1155/2012/232464).
2. The Thioredoxin System
The TRX system mainly comprises TRX, TRX reductase,
TRX interacting protein ((TXNIP), vitamin D3-upregulated
protein-1 ((VDUP)-1) or TRX-binding protein (TRXBP)),
and the PRDXs [3]. The TRX system is involved in protein
assembly and plays a key role in cellular redox maintenance.
Under physiological conditions, intra- and extracellular
reactive oxygen species (ROS) modulate metabolic, signal-
ing, and transcriptional processes within the cell. However,
pathological dysregulation of the redox balance could con-
tribute to CVDs [4, 5]. Cellular redox homeostasis is tightly
regulated by the coordinated action of NADPH oxidases, the
TRX system and glutathione (GSH) [6], among others. The
TRX system and GSH are thiol reduction systems with a
key role in the defense against excessive ROS production,
as well as in the modulation of signaling processes such
as inflammation, cellular proliferation, and apoptosis [7–9].
These molecules maintain the intracellular milieu in a
reduced state. GSH is used by the GSH peroxidase to reduce
peroxides, producing oxidized GSH (GSSG) while GSH
reductase reduces this oxidized form to GSH. The antiox-
idant properties of TRX result from PRDX action, which
recycle H2O2 through reduction of several hydroperoxides
into water and alcohol (Figure 1).

























Figure 1: Schematic diagram showing the maintenance of the cellular redox homeostasis by the NADPH oxidase, GSH, and the TRX
system. PRDXox-oxidized PRDX; PRDXred-reduced PRDX; TRX-S2-oxidized TRX; TRX-SH2-reduced TRX; GR-GSH reductase; GPx-GSH
peroxidase.
Depending on their cellular location, TRX/PRDX may
exert diﬀerent functions than their known chaperone and
antioxidant activities. This process can be described with
the so-called “Moonlighting proteins” theory [10]. This
idea supports the notion that one gene = one protein =
one function is simple and old-fashioned because large
number of proteins have two or more functions. This theory
might not apply to every protein but it seems to be right
for TRX/PRDX. Under certain circumstances, mainly pro-
oxidative conditions, TRX and PRDX could be released to
the extracellular milieu [11, 12] although their traﬃcking
mechanisms are not yet fully described.
2.1. Intracellular TRX. TRXs are a class of small redox
molecules (∼12 kDa) present in prokaryotes and eukaryotes
and are essential for cellular viability [13]. So far, 3 human
TRX variants have been characterized codified by diﬀerent
genes. TRX1 is localized under resting conditions in the
cytosol but can be translocated upon stress conditions [14]
(e.g., it can be found in an oxidized form in the nucleus of
exponential growing cells [15] (Figure 2)), TRX2 is mito-
chondrial [16, 17], and SpTRX [18] is abundantly expressed
in spermatozoa. TRX has a redox active disulfide/dithiol site
within 2 conserved Cys residues [19], and it functions as
an antioxidant molecule by protecting cells against H2O2
[20], regulating heme-oxygenase 1 (HO-1) expression [21],
or inducing manganese superoxide dismutase (MnSOD) in
the mitochondria [22]. Moreover, it has a protective role
against nitric-oxide- (NO-) induced stress, regulating NO
synthases activity [23] and through other NO regulating
processes [24]. In addition to its role as antioxidant protein,
TRX interacts with numerous signaling molecules (including
apoptosis signal-regulating kinase 1 (ASK1) and TXNIP)
and transcription factors such as nuclear factor-kappa B
(NF-κB) and activating protein 1 (AP-1). TRX function can
be regulated by redox modification (e.g., NO increases S-
nitrosylation of TRX stimulating TRX activity [25]) or by
TXNIP binding [26] (reducing TRX activity), among other
mechanisms.
Regarding intracellular TRX in vivo functions, as TRX-
1 KO mice are lethal, some information has been obtained
from studies performed in TRX transgenic (Tg) mice [27].
TRX overexpression in mice protects placenta from oxidative
stress and fetal growth by augmenting glucose availability
[28], and it also functions as a shelter against apoptosis
induced by extensive oxidation in diabetic embryopathy
[29] or streptozotocin-induced diabetic osteopenia [30].
Furthermore, TRX is able to protect the lung injury provoked
by diesel exhaust particles (DEPs) derived from diesel
engine-powered automobiles and industrial machines. This
protective role, played through AKT modulation, is reflected
in the augmented TRX levels in control cells induced by DEP
[31]. Also, mediated by AKT signaling, TRX protects neurons
against apoptosis during brain focal ischemia [32].
Thus, the major role of TRX in the redox balance is
supported by the numerous data regarding the protection
exerted by TRX against excessive oxidative damage in diﬀer-
ent diseases and the embryonic lethality of KO mice for TRX.
2.2. Intracellular PRDX. PRDXs are a recent discovery
among the peroxidases lacking the hemo group. PRDX pro-
tein levels are very abundant, around 0.1–1% of total soluble
protein in mammals, and they are ubiquitously distributed
in all organisms [12, 33]. PRDXs are thiol-specific enzymes
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Figure 2: Schematic diagram showing PRDX1/TRX main cellular location under nonstress conditions (left), under oxidative stress (right)
and traﬃcking mechanisms (right).
lacking selenium, and they use their active sites to reduce
peroxides and scavenge ROS [12]. Mammal cells express
6 PRDX isoforms (PRDX 1–6): 1, 2, and 6 are cytosolic,
and 3 and 5 are mitochondrial, while 4 is described as a
secretory protein inmost tissues [34]. Every isoform contains
a conserved Cys residue, which is the primary site for H2O2
oxidation, and they can be further classified according to
their Cys residues (PRDX1-4 belongs to the 2-Cys subfamily,
PRDX5 or atypical 2-Cys and PRDX6 or 1-Cys PRDX) [35].
PRDXs scavenge H2O2 more eﬃciently than other sys-
tems such as catalase due to its higher aﬃnity for H2O2
[36]. PRDX can modulate NADPH oxidase activity through
H2O2 inactivation [37]. In addition, PRDX can also reduce
peroxynitrites levels through peroxynitrites reductases [38].
Among the mechanisms modifying PRDX functions, several
posttranslational modifications have been described, such
as nitrosylation [39], glutathionylation [40], phosphoryla-
tion, and the hyperoxidation of its active site [41], which
stimulates its chaperone activity [42]. For example, under
low H2O2 concentrations produced in conditions of cellular
homeostasis PRDX forms low-molecular-weight oligomers,
exerting peroxidase activity. However, under significant
changes in H2O2 concentration, PRDX experiences struc-
tural changes and forms high-molecular-weight oligomers
and acquires chaperone activity [43, 44]. Similarly to TRX,
PRDX interacts with several proteins (e.g., cyclophilin A,
macrophage inhibitory factor, etc.) and can modulate the
function of these binding proteins, in a dependent or inde-
pendent manner of the PRX redox status [35].
Mice lacking PRDX1 are viable with a phenotype char-
acterized by hemolytic anemia caused by an increased ROS
production by red blood cells (RBCs). Furthermore, PRDX1
has tumor suppressor properties as PRDX1 KOmice show an
increased rate in malignant tumors as they age, which can be
explained by the excessive accumulation of damaged tissue
due to extreme ROS production [45]. Similarly to PRDX1
KO mice, targeted disruption of PRDX2 causes cysteine
oxidation of several proteins on RBCs membranes, which
finally results in augmented levels of denatured protein,
cell toxification, and hemolysis [46]. PRDX2 also has been
identified as a tumor suppressor gene [47]. Accordingly,
PRDX3 (also known as MER5) KO mice are characterized
by increased ROS production in macrophages and develop
more severe lung injury upon Lipopolisaccharide (LPS)
induction, possibly due to an excessive DNA and protein
oxidative damage and inflammatory cell infiltration [48]. In
fact, it has been calculated that almost 90% of H2O2 targets
PRDX3 within the mitochondrial matrix, playing a major
role in redox signaling in the mitochondria [49], protecting
the cells against apoptosis induced by excessive damage
to mitochondrial macromolecules [50]. PRDX3 absence is
also involved in mitochondrial dysregulation associated with
obesity, through increased protein carbonylation and ROS
production [51]. It is noteworthy that PRDX3 KO adipocytes
accumulate more fat than wild type due to hypertrophy and
defects in the levels of enzymes implicated in glucose/lipid
metabolism [51]. PRDX4 is mostly a secretory protein, while
it is attached to the endoplasmic reticulum (ER) membrane
of spermatogenic cells in mature testes. In these cells PRDX4
protects from cell death through its antioxidant properties,
nonetheless PRDX4 KO spermatozoa shows normal fertiliza-
tion [52]. To our knowledge there is no PRDX5 KO strain,
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although it has been described that PRDX5 overexpression
prevents ROS production and p53-dependent apoptosis [53].
Nevertheless, KOmice for PRDX6, the only 1-Cysmember of
the peroxiredoxin family, were more vulnerable to ischemic
reperfusion injury as shown by increased infarct size and
higher amount oxidative stress [54]. In agreement, PRDX6
overexpression functions as a shelter in mouse lungs against
toxicity of hyperoxia [55].
On the whole, the plethora of data regarding the
diﬀerent isoforms of PRDX demonstrate that every subunit,
independently of its location, is amember of one of themajor
cellular systems in charge of scavenging prooxidant species
and thus in the maintenance of cellular redox status.
2.3. Extracellular TRX. TRX expression can be augmented
very fast under stress and is secreted by normal and tumor
cells although its secretion does not seem to follow a classical
Golgi apparatus pathway [11]. TRX location is regulated
by TXNIP binding [26] and facilitates TRX transport from
cytoplasm to the membrane under oxidative stress [14].
Another mechanism that can be involved in TRX active
secretion is the exosomal pathway. Exosomes are small
microparticles released by cells upon activation or apoptosis.
These vesicles have been implicated in thrombosis, diabetes,
inflammation, atherosclerosis, and vascular cell proliferation
[56]. Proteomic studies have described the presence of TRX
in exosomes in B cells [57], bladder cancer cells [58],
colorectal cancer cells [59], and urine [60] (Figure 2).
There is also a truncated form of TRX that corresponds
to the last 80–84 amino acids from the N-terminal end,
named TRX80, and it is present in plasma where it was firstly
identified as a stimulating factor of eosinophils cytotoxicity
[61]. It is possibly a result of protease activity but this process
is still unknown (Figure 2). Recombinant TRX80 is a potent
mitogenic cytokine for peripheral blood mononuclear cells
(PBMCs), an eﬀect not shared by TRX [62]. TRX80 diﬀers
from TRX because it forms a dimer lacking reductase activity
and its activity is independent of the Cys residues from
the TRX active site. The main cellular target for TRX80
are PBMCs in which it induces a Th1 response via IL12
production [63].
Extracellular TRX is present in the circulation and its
levels are increased under oxidative stress or inflammation
[64] (Figure 2). TRX has been pointed out as a biomarker
in numerous oxidative and inflammatory diseases such as
rheumatoid arthritis (RA) in which plasma TRX levels of
normal subjects were significantly lower than those of RA
patients and correlated with RA disease activity and C-
reactive protein [65]. TRX levels were increased in patients
with systemic inflammatory stress syndrome (SIRS)/sepsis
compared to control subjects [66].
2.4. Extracellular PRDX. PRDX1 can be found inside the
Golgi apparatus on endothelial cells (ECs) [67], and under
phorbol 12-myristate 13-acetate (PMA) stimulation PRDX1
is translocated to the cellular membrane [68], as also
showed for PRDX6 in polymorphonuclear cells (PMNs) [69]
(Figure 2). PRDX might also be secreted by lung cancer cells
through a nonclassical pathway [70, 71]. Nonetheless, the
extracellular function of PRDX is still unknown. Unlike the
well-described function of intracellular PRDX1, membrane
PRDX6 helps in the maintenance of an optimal NADPH
oxidase activity [69]. A number of chaperones, including
TRX and HSPs, are released by stressed or dying cells, acting
as an endogenous warning system through binding of these
signals to receptors on the outer membrane [72–75]. Most of
these signals are recognized by Toll-like receptor 4 (TLR4)
[74, 75]. Accordingly, PRDX1 binds TLR4 and stimulates
proinflammatory cytokine production in macrophages and
dendritic cells, which suggests that PRDX could be acting
as damage-associated molecular-pattern molecule (DAMP).
Its traﬃcking seems to be dependent on PRDX binding to
protein kinase C (PKC) through microvesicles [76]. In fact,
exosomes can be participating in active transport of PRDX
since proteomic studies have described PRDX in exosomes
in B cells [57], bladder cancer cells [58], breast cancer cells
[77], breast milk [78], colorectal cancer cells [59], and saliva
[79] (Figure 2).
Thus, it is tempting to speculate that extracellular levels
of PRDX/TRX result from a cellular response to high oxidant
conditions in the outer milieu.
3. TRX/PRDX in Atherothrombosis
Atherothrombosis is an immune-inflammatory disease, orig-
inated by the subendothelial accumulation of LDLs, that can
be oxidized by ROS. Oxidative stress is involved not only in
the first stages of atherogenesis by modifying LDLs or NO,
but also in later stages of atherothrombosis by modulating
the expression of proteases that weakens the fibrous cap
[80, 81]. ROS overproduction also produces direct damage
to macromolecules such as lipids, nucleic acids, and proteins
[82]. Furthermore, ROS can act as signaling molecules by
inducing the activation of several cells from the vasculature.
For example, through LDL oxydation and/or direct cell
targeting, ROS can induce endothelial dysfunction and
further leucocyte activation, deposition, and extravasation.
In addition, ROS are clearly involved in the activation of
vascular smooth muscle cells (VSMCs) from the lesion and
sustain foam cell formation. Thus, pathological ROS over-
production is a main feature in atherogenesis and plaque
rupture, which finally results in almost 70% of the clinical
events [83].
Among the diﬀerent systems involved in the redox
maintenance in the vasculature, one of the most active is the
TRX system. It is present in ECs [14, 84], VSMCs [85, 86],
monocytes/macrophages [87, 88], RBCs [89, 90], and PMNs
[90, 91]. Since TRX and PRDX are present in the atheroscle-
rotic plaque and they can modulate diﬀerent mechanisms
involved in CVDs, several studies have addressed their role
as diagnostic, prognostic, and therapeutic biomarkers.
3.1. TRX. TRX is abundantly expressed in the vasculature,
and its levels are increased under oxidative stress, possibly
as a response mechanism to augmented ROS production
[19]. Besides, TRX expression in the endothelium and
Oxidative Medicine and Cellular Longevity 5
in macrophages is augmented in atherosclerotic patients
[92] and in arteries damaged by the balloon model [93].
More recently, TRX has been pointed as a possible marker
for unstable atherosclerotic plaques due to its association
with oxidative stress and intraplaque hemorrhage in culprit
lesions [94]. TRX reductase is as well overexpressed in ath-
erosclerotic plaques, maybe synthesized by macrophages
engulfing oxLDLs [95].
The antioxidant eﬀects of TRX are shown when overex-
pressed in mouse hearts, protecting them from myocardial
infarction and displaying significantly improved postis-
chemic ventricular recovery [96]. The positive eﬀects of TRX
in myocardial infarction are also due to its neoangiogenic
properties as shown in diﬀerent murine models [97, 98].
On the other hand, TRX can function as a signaling
molecule by decreasing pressure-overload cardiac hypertro-
phy [99], maybe through upregulation of miR-98 [100].
However, there is a controversy about this matter because
almost at the same time it was published another article
in which the authors described that activation of TRX
participates in the development of pressure-overload cardiac
hypertrophy. In this respect, animals overexpressing TXNIP
developed less hypertrophy [101]. Furthermore, transverse
aortic constriction increased TRX activity accompanied by
a 40% reduction in TXNIP levels [101]. Whether variations
in TXNIP and TRX levels/activity reflect an increase in
oxidative stress or they act as signaling molecules is still a
matter to elucidate [102].
Recent studies have shown that extracellular TRX can
inhibit interleukin-1 expression stimulated by LPS in mono-
cyte-derived macrophages [103]. Besides, TRX1 administra-
tion has beneficial eﬀects on myosin-induced autoimmune
myocarditis through inhibition of inflammatory mediators
and macrophage infiltration [104] and TRX1 also protects
from reperfusion-induced arrhythmias [105]. Furthermore,
TRX administration has been also shown to be benefi-
cial in cerebral ischemia/reperfusion injury reducing the
infarcted area through its antioxidant properties [106]. As
an additional support for the beneficial eﬀects of TRX in
therapeutics, it is to note that TRX-1 gene delivery protects
hypertensive rats from myocardial infarction through HO-
1/B-cell lymphoma 2 (BCL-2) [107].
Regarding cardiovascular diseases, TRX levels are ele-
vated in plasma from atherothrombotic patients [108, 109],
and high homocysteine plus low TRX is related to CAD
severity [110]. Furthermore, TRX was elevated in patients
following angioplasty, and there was an association with
increased TRX levels and decreased rate of restenosis at
follow-up angiography (6 months) [111]. We have recently
reported an increase in serum TRX from abdominal aortic
aneurysm (AAA) patients compared with control subjects.
Besides, TRX correlates with AAA size and expansion rate
which suggests that TRX could be a good biomarker of AAA
evolution [91].
3.2. PRDX. PRDX expression can be modified by proox-
idative stimulus such as LPS or the phorbol ester 12-O-tet-
radecanoylphorbol- 13-acetate (TPA) [88, 112]. Attention to
PRDX as a major regulator of H2O2 homeostasis is growing
[34]. In cells stimulated with platelet-derived growth factor
(PDGF) or tumor necrosis factor alpha, PRDX overexpres-
sion or silencing provoked, respectively, reduction or in-
crease of H2O2 levels [113]. Moreover, through H2O2 scav-
enging, PRDX can inhibit the NF-κB pathway and conse-
quently the inflammatory response [114]. Diﬀerent PRDX
isoforms seem to modulate diﬀerent cellular responses. For
example, transfection of VSMCs from rat pulmonary artery
with an expression plasmid for PRDX1 increases pro-
liferation rate significantly [115]. PRDX1 also diminishes
leucocytes activation and adhesion to vascular endothelium.
Double KO mice for PRDX1 and ApoE chow fed showed
larger atherosclerotic lesions and macrophages enriched
than ApoE KO mice [116]. KO mice for PRDX2/ApoE
showed exacerbated atherosclerotic lesion formation depen-
dent both on vascular and hematopoietic cells. Besides,
immune cells accumulation in the atherosclerotic lesions is
increased due to PRDX2 absence and also redox-dependent
signaling PRDX2 [117]. Moreover, PRDX2 modulates PDGF
signaling, inhibiting thereby cell proliferation and migration
[113, 118]. Using diﬀerent in vivo models, it was shown
that CD36 KO mice produce lower levels of ROS, along
with an increase in heme-oxygenase1 (HO-1) and PRDX2.
Furthermore, NF-E2-related factor-2 (Nrf2), a transcription
factor in charge of the transcriptional regulation of HO-1
and PRDX2, knockdown led to increased ROS production
and a prothrombotic phenotype under FeCl3 treatment, a
similar phenotype to that of PRDX2 KO mice [119]. Re-
garding PRDX2 and vascular diseases, it has been recently
shown that PRDX2 is overexpressed in ruptured AAA tissue
compared with nonruptured [120]. This could be associated
with the increased oxidative stress observed in AAA tissue,
which produces 2.5 times higher superoxide than adjacent
non-AAA tissue and 10 times higher than nonpathological
aorta [121].
Besides, PRDX3 overexpression prevents ventricular re-
modeling and cardiac failure after myocardial infarction
in mice [122]. As mentioned above, PRDX6 protects
mice against ischemic reperfusion injury [54]. Although,
little is known about circulating levels of PRDX, we have
recently described high PRDX1 levels in serum from AAA
patients [90]. Besides, PRDX1 levels correlated positively
with size and expansion rate of AAA, suggesting its po-
tential role as diagnostic and prognostic biomarker for
AAA.
4. Conclusion
On the whole, we have summarized several findings that
demonstrate the major role of the TRX system in the
maintenance of the redox status in CVDs. Furthermore, the
extracellular levels of PRDX/TRX seem to be related with a
prooxidative scenario and there is growing data suggesting
their potential role as biomarkers for oxidative-stress-related
diseases. Finally, their value as useful therapeutic tools is
being tested and future studies are necessary to validate thier
prospective beneficial eﬀects in CVDs.
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